GatewaySeq, a genetic test for solid tumors, is a success for WashU School of Medicine

GatewaySeq, a cancer sequencing test developed at Washington University School of Medicine, received approval from the Centers for Medicare and Medicaid Services (CMS) in 2023, and is successfully in use at Siteman Cancer Center.
The success is a milestone for Eric Duncavage, MD, Professor of Pathology and Immunology. Duncavage and his collegues created a rapid, inexpensive panel designed for initial diagnosis, prognosis, and therapy selection in most solid tumors.
GatewaySeq is meant to be used as a frontline assay to quickly identify common clinically significant mutations and actionable genomic markers to help guide treatment decisions.
GatewaySeq testing is available at all hospitals that use Washington University Pathology Services including Barnes-Jewish Hospital and Siteman Cancer Centers. The recent CMS approval sets the stage for expanded utilization of the test, which has the advantage of in-house expertise and resources.
Subscribe now ➤ bit.ly/2NNQiyM
For more great content from HEC Media check us out at:
Facebook ➤ bit.ly/1WPZEek
Twitter ➤ bit.ly/22qZDNU
Instagram ➤ bit.ly/1THSOnM